The p53-SLP vaccine combined with cyclophosphamide therapy is evaluated by Vermeij et al. for treating patients with recurrent ovarian cancer in a single-arm phase II study (Vermeij et al., 2012). This evidence concerns the gene TP53 and ovarian cancer.